Calcium chloride injection to reduce atrial fibrillation after heart surgery
Post Operative Atrial Fibrillation: Alleviation by Calcium Chloride Injection Into Cardiac Ganglionic Plexus During Coronary Artery Bypass Grafting.
PHASE3 · Helwan University · NCT06378021
This study tests if injecting calcium chloride during heart surgery can help prevent atrial fibrillation in patients after the procedure.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 74 Years |
| Sex | All |
| Sponsor | Helwan University (other) |
| Locations | 1 site (Cairo, Abassia Cairo) |
| Trial ID | NCT06378021 on ClinicalTrials.gov |
What this trial studies
This study investigates the effect of injecting calcium chloride into the major atrial ganglionic plexus during on-pump coronary artery bypass graft (CABG) surgery to reduce the incidence of postoperative atrial fibrillation. It is a prospective, two-armed randomized controlled trial where one group receives calcium chloride and the other receives sodium chloride as a control. The hypothesis is that calcium chloride can induce autonomic neurotoxicity, thereby suppressing the neural networks responsible for initiating atrial fibrillation. The study aims to evaluate the effectiveness of this intervention in preventing atrial fibrillation in the first week post-surgery.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are scheduled for on-pump CABG surgery.
Not a fit: Patients over 75 years old, those with preoperative atrial fibrillation, or significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the occurrence of atrial fibrillation in patients undergoing CABG, leading to improved recovery and outcomes.
How similar studies have performed: While the approach of using calcium chloride in this context is novel, similar studies targeting atrial fibrillation prevention have shown varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1) Patients more than 18 years old 2 ) patients undergoing On pump CABG Exclusion Criteria: 1. patients \>75 years of age 2. Patients with Pre operative Atrial fibrillation 3. Patients with Significant valvular disease 5. Ejection fraction \<30% 6. Combined surgery of any kind 7. Congenital heart disease 8. Abnormal severe liver or kidney dysfunction. 9. Patients undergoing Off-pump CABG 10. Poorly controlled hyperthyroidism 11. Refusal to enrollment.
Where this trial is running
Cairo, Abassia Cairo
- Ain shams university — Cairo, Abassia Cairo, Egypt (RECRUITING)
Study contacts
- Principal investigator: Abdelhameed I Ebid — Prof
- Study coordinator: Nadine O Elgarhi, pharmacist
- Email: nadinesadek2013@hotmail.com
- Phone: 01144249948
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Atrial Fibrillation, Atrial fibrillation, Calcium chloride, On pump Coronary artery bypass graft